About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Part 1: Evolution and Development into Theranostics
If clinicians know in advance which drugs will work for individual patients, they can eliminate trial-and-error prescribing, decrease costs, and improve outcomes. Part 1 of a three-part series reviews the history, barriers, and outlook of this emerging practice.
F. Randy Vogenberg, PhD, RPh; Carol Isaacson Barash, PhD; and Michael Pursel, RPh, MBA
A Concise Case Report and Literature Review
The case of a 23-year-old African-American woman who underwent live donor kidney transplantation illustrates the complexity of drug interactions involving the cytochrome P450 system.
Mary Choy, PharmD
Part 3: Policies and Practices Regarding Dietary Supplements In Health Care Facilities
Despite the increased acceptance of CAM and integrative medicine, many inpatient institutions have not established formal policies concerning their use. In the final article of this series, the challenges of integrating CAM (such as what to do about patients bringing dietary supplements into the hospital) are discussed.
C. Lee Ventola, MS
Topics include aliskiren/amlodipine (Tekamlo) tablets for hypertension, bimatoprost ophthamic solution (Lumigan 0.01%) for glaucoma, and hexaminolevulinate HCl (Cysview Solution) for the detection of bladder cancer.
Marvin M. Goldenberg, PhD, RPh, MS
Selected sessions address antiplatelet therapies for acute coronary syndrome
and cardiac and stroke risk reduction in patients with heart failure and atrial fibrillation.
The World Economic Forum has concluded that the only path to improved health is through disease prevention.
David B. Nash, MD, MBA
A Destination Without a Map
If we hold health care workers accountable for achieving the "five rights" of patient safety, we should give them the authority to design their own systems for achieving these outcomes.
Matthew Grissinger, RPh, FASCP
The FDA has been slow in issuing guidelines to simplify drug naming and labeling, but that could change quickly.
FDA approvals, drug indications, product recalls, industry updates, and research news
A New Approach to the Treatment of Women with Postmenopausal Osteoporosis
Denosumab (Prolia) for women with postmenopausal osteoporosis
Wendy Green, PharmD, MPA